Drug-free relief from chronic constipation may come from a new vibrating pill
People who struggle with chronic constipation have a new drug-free option to help get things moving again. It’s a first-of-its-kind capsule about is the size of a regular pill – but instead of releasing medication after it’s swallowed, it vibrates to stimulate the colon. The capsules, called Vibrant, was cleared by the US Food and […]
FDA grants marketing authorization for Vibrant®, a new first-in-class, drug-free treatment for adults with chronic idiopathic constipation
Vibrant Gastro Inc. announced today that the Food and Drug Administration (FDA) granted marketing authorization for the Vibrant®, an orally administered drug-free capsule, for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. Vibrant®’s […]
Hope for chronic constipation sufferers thanks to vibrating pill that can ‘double the number of weekly bowel movements’
The gadget, called Vibrant and about the size of a fish-oil supplement, sends out pulses that, the designers claim, stimulate natural movements in the gut Capsule is still under development by its Israeli manufacturer Latest data from its largest trial so far, involving over 300 patients, suggests it can double the number of weekly bowel […]
A vibrating pill for constipation heads to the FDA after completing phase 3 study
A small, vibrating pill designed to help people with chronic constipation cleared a clinical study and is headed to the FDA for final review. Vibrant Gastro is putting forward its approach as a drug-free alternative for infrequent or difficult bowel movements. Swallowed along with a glass of water, the disposable pill—about the size of an […]
Vibrant’s Novel Drug-Free Treatment Demonstrates Positive Efficacy and Safety Results in Adults with Chronic Idiopathic Constipation in Pivotal Phase 3 Study
The Phase 3 data met all primary endpoints for complete spontaneous bowel movements (CSBMs) per week and showed significant improvement in secondary outcomes versus placebo Data validates Vibrant as a safe and well-tolerated option to address unmet treatment needs in chronic idiopathic constipation (CIC) Company submitted Phase 3 data to the U.S. Food and Drug […]
Vibrant Gastro Received Honorable Mention in Health Category of Fast Company’s 2022 World-Changing Ideas Awards
Vibrant Gastro received honorable mention in the health category for its innovative drug-free treatment for chronic constipation utilizing an entirely different approach compared to traditional drug-based treatments. The winners of Fast Company’s 2022 World Changing Ideas Awards were announced today, honoring clean technology, innovation in healthcare, brave new designs for cities and buildings, and other […]
Vibrant to Present Phase III Data at the 2022 Digestive Disease Week (DDW) Conference
YOKNEAM ILLIT, Israel, April 13, 2022 /PRNewswire/ — Vibrant, a medical technology company that developed a proprietary, biocompatible treatment for chronic idiopathic constipation (CIC), announced today that an abstract titled, “Efficacy and Safety of Vibrant® Capsule for Chronic Idiopathic Constipation (CIC): Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III Trial” has been accepted for an abstract presentation at the 2022 […]
Pharma must embrace the shift to technological solutions in healthcare
Big Pharma’s rigid business model has been successful for such a long time that it makes change more challenging. But Yoav Shaked, an investor in healthtech companies, writes that there are signs of a shift in the healthcare industry, with many patients embracing a new generation of health technology. The pharmaceutical industry did well out […]
Vibrant submits new constipation treatment for FDA
Vibrant reports positive efficacy and safety in a pivotal study for its namesake Vibrant System Vibrant, announced that the Vibrant System for chronic idiopathic constipation met its primary safety and efficacy endpoints in the V-270 pivotal trial. Based on the study’s positive findings, CEO Lior Ben Tsur announced the company has submitted a de novo […]
U.S. healthcare sees a paradigm shift in chronic treatment
Chronic conditions are the main drivers of the $3.8 trillion healthcare costs per annum in the United States, and are some of the most significant causes of death and disability. Diabetes and arthritis have long been known as chronic conditions. The advent of cancer immuno-therapies (such as Keytruda, Opdivo, and Yervoy) has caused some to […]